Dyne Therapeutics, Inc. (DYN) Stock

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN) stock trades at $15.62 with a market capitalization of $2.92B. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.84, reflecting a net loss over the last twelve months, price-to-book of 3.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.33 and $27.31, and currently trades 42.8% below its 52-week high.

On profitability, Dyne Therapeutics, Inc. generates a return on equity (ROE) of -64.30% (negative, reflecting a net loss), return on capital employed of -58.62%.

Dyne Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Dyne Therapeutics, Inc. reported revenue of $1.4B rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-446.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-520.0M.

Borrowings fell from $9.0B to $20.0M, cash from operations was $-403.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -92.5% over five years, and was -45.9% in the most recent year.

The share price itself has compounded at 1.6% a year over five years, 11.0% over three, 46.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Dyne Therapeutics, Inc. (DYN) — frequently asked questions